Rapid, Direct-to-Digital Prostate Biopsy Pathology Evaluated
By LabMedica International staff writers Posted on 13 May 2021 |

Image: Standard hematoxylin-eosin sections are unaffected by processing and imaging by clearing histology with multiphoton microscopy (CHiMP). Portions of the same core biopsy were submitted directly to standard processing (A) or processed by CHiMP and subsequently embedded in paraffin, sectioned, and stained (B), showing equivalent coloration and morphology (Photo courtesy of Yale School of Medicine)
Increasing adoption of digital pathology promises marked improvements in reproducibility, efficiency, and accuracy of tissue-based diagnostics by facilitating routine remote expert consultation and enabling computerized image analysis for clinical use.
Clearing histology with multiphoton microscopy (CHiMP) is a new technique for tissue processing and image acquisition that eliminates conventional paraffin embedding by incorporating fluorescent staining during preparation steps and then uses a fast, high-resolution laser-scanning multiphoton microscope to acquire images on intact tissue.
Medical Laboratory Scientists at Yale School of Medicine (New Haven, CT, USA) analyzed samples from 40 patients with a high likelihood of prostate cancer based on magnetic resonance imaging consented to investigational core biopsy. A subset of samples was used for direct comparison of physical slide preparation effects and time-tracking determination with multiphoton microscopy. Twenty samples were processed for diagnostic comparison between multilevel digital slides and subsequently produced physical slides. A reference diagnosis based on all data was established using grade groups. Level of diagnostic match and requests for immunohistochemistry were compared between physical and digital diagnoses. Immunohistochemical staining and length measurements were secondary outcomes.
Imaging of pathologist study specimens was performed in a prototype specialized ultrafast multiphoton microscope supplied by the startup company Applikate Technologies (Weston, CT, USA) that incorporates a femtosecond pulsed laser and a 0.95 numerical aperture benzyl alcohol/benzyl benzoate immersion objective. All physical tissue slides were imaged using an Aperio ScanScope (Leica Biosystems, Wetzlar, Germany) at ×40 equivalent resolution for digital storage and preparation of figures.
The scientists reported that interpretations based on direct multiphoton imaging yielded diagnoses that were at least as accurate as standard histology; cancer diagnosis correlation was 89% (51 of 57) by physical slides and 95% (53 of 56) by multiphoton microscopy. Grade-level concordance was 73% (44 of 60) by either method. Immunohistochemistry for routine prostate cancer–associated markers on these alternatively processed tissues was unaffected. Alternatively processed tissues resulted in longer measured core and cancer lengths, suggestive of improved orientation and visualization.
The authors concluded that their study demonstrates the viability of using direct digital imaging for definitive microscopic evaluation of tissue without requiring physical slide preparation for gold standard–level diagnosis. Overall, results support practical relevance of the CHiMP technique for prostate biopsy evaluation, with the potential to significantly advance prostate cancer diagnostics, and meriting continuing detailed validation as a process incorporated into clinical diagnostic practice. The study was published in the May, 2021 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Yale School of Medicine
Leica Biosystems
Clearing histology with multiphoton microscopy (CHiMP) is a new technique for tissue processing and image acquisition that eliminates conventional paraffin embedding by incorporating fluorescent staining during preparation steps and then uses a fast, high-resolution laser-scanning multiphoton microscope to acquire images on intact tissue.
Medical Laboratory Scientists at Yale School of Medicine (New Haven, CT, USA) analyzed samples from 40 patients with a high likelihood of prostate cancer based on magnetic resonance imaging consented to investigational core biopsy. A subset of samples was used for direct comparison of physical slide preparation effects and time-tracking determination with multiphoton microscopy. Twenty samples were processed for diagnostic comparison between multilevel digital slides and subsequently produced physical slides. A reference diagnosis based on all data was established using grade groups. Level of diagnostic match and requests for immunohistochemistry were compared between physical and digital diagnoses. Immunohistochemical staining and length measurements were secondary outcomes.
Imaging of pathologist study specimens was performed in a prototype specialized ultrafast multiphoton microscope supplied by the startup company Applikate Technologies (Weston, CT, USA) that incorporates a femtosecond pulsed laser and a 0.95 numerical aperture benzyl alcohol/benzyl benzoate immersion objective. All physical tissue slides were imaged using an Aperio ScanScope (Leica Biosystems, Wetzlar, Germany) at ×40 equivalent resolution for digital storage and preparation of figures.
The scientists reported that interpretations based on direct multiphoton imaging yielded diagnoses that were at least as accurate as standard histology; cancer diagnosis correlation was 89% (51 of 57) by physical slides and 95% (53 of 56) by multiphoton microscopy. Grade-level concordance was 73% (44 of 60) by either method. Immunohistochemistry for routine prostate cancer–associated markers on these alternatively processed tissues was unaffected. Alternatively processed tissues resulted in longer measured core and cancer lengths, suggestive of improved orientation and visualization.
The authors concluded that their study demonstrates the viability of using direct digital imaging for definitive microscopic evaluation of tissue without requiring physical slide preparation for gold standard–level diagnosis. Overall, results support practical relevance of the CHiMP technique for prostate biopsy evaluation, with the potential to significantly advance prostate cancer diagnostics, and meriting continuing detailed validation as a process incorporated into clinical diagnostic practice. The study was published in the May, 2021 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Yale School of Medicine
Leica Biosystems
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more